MHRA Publishes Guidance Note If No Brexit Deal

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) on Thursday January 3, 2019 issued “Further guidance note on the regulation of medicines, medical devices and clinical trials if there’s no Brexit deal” to document how the MHRA proposes to regulate medicines if there is “no deal” for “Brexit”.

“If there’s no deal, the UK’s participation in the EMRN (EU medicines regulatory network) would cease and the MHRA would take on the functions currently undertaken by the EU for human medicines on the UK market.”

For more details click the link below to see the full MHRA Guidance Document.